CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

ambroxol

Small moleculeexperimental

Ambroxol is a drug that breaks up phlegm, used in the treatment of respiratory diseases associated with viscid or excessive mucus. Ambroxol is often administered as an active ingredient in cough syrup. — Wikipedia

Clinical trial activity

34 trials · 33 clinical orgs · 0 marketing orgs

Phase 1
14
Phase 2
19
Phase 3
9
Phase 4
1

Earliest trial started Jun 1, 1999 (NCT02194296)

Timeline

1990s

  1. Jan 1, 1999

    Earliest Phase 1 Sponsor(trial)

2000s

  1. Jan 1, 2005

    Earliest Phase 3 Sponsor(trial)

2010s

  1. Jan 1, 2011

    Earliest Phase 2 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1
Mol. weight
378.11 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • acebrophylline
  • acebrophylline
  • acebrophylline
  • acebrophylline
  • ambromucil
  • ambromucil
  • ambroxils
  • ambroxol
  • ambroxol
  • ambroxol
  • ambroxol
  • ambroxol
  • ambroxol
  • ambroxol
  • ambroxol acefyllinate
  • ambroxol acefyllinate
  • ambroxol acefyllinate
  • ambroxol hcl
  • ambroxol hcl
  • ambroxol hcl
  • ambroxol hydrochloride
  • ambroxol hydrochloride
  • ambroxol hydrochloride
  • ambroxol hydrochloride
  • ambroxol hydrochloride
  • ambroxol hydrochloride
  • ambroxol hydrochloride
  • ambroxol theophyllinacetate
  • ambroxol theophyllinacetate
  • ambroxol-theophylline-7-acetate
  • ambroxolum
  • ambroxolum
  • benzyl ambroxol
  • bisolvon metabolite viii
  • bisolvon metabolite viii
  • bromhexine metabolite viii
  • bromhexine metabolite viii
  • bromhexine-metabolite viii
  • bromhexine-metabolite viii
  • broncomnes
  • broncomnes
  • cyclohexanol, 4-((2-amino-3,5-dibromobenzyl)amino)- (e)-
  • cyclohexanol, 4-((2-amino-3,5-dibromobenzyl)amino)- (e)-
  • ht-002-01
  • lasolvan
  • n-(2-amino-3,4-dibromociclohexil)-trans-4-aminociclohexanol
  • n-(2-amino-3,4-dibromociclohexil)-trans-4-aminociclohexanol
  • n-(2-amino-3,4-dibromocyclohexyl)-trans-4-aminocyclohexanol
  • n-(2-amino-3,4-dibromocyclohexyl)-trans-4-aminocyclohexanol
  • surfolase
  • surfolase
  • trans-4-((2-amino-3,5-dibromobencil)amino)ciclohexanol
  • trans-4-((2-amino-3,5-dibromobencil)amino)ciclohexanol
  • trans-4-((2-amino-3,5-dibromobenzyl)amine)cyclohexanol
  • trans-4-((2-amino-3,5-dibromobenzyl)amine)cyclohexanol
  • trans-4-((2-amino-3,5-dibromobenzyl)amino)cyclohexanol
  • trans-4-((2-amino-3,5-dibromobenzyl)amino)cyclohexanol

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07285369N/AMar 1, 2025Agyany Pharma LTD
NCT06614894Phase 2/Phase 3 (Phase 3)Dec 1, 2024Lysosomal and Rare Disorders Research and Treatment Center, Inc.
NCT06193421Phase 1/Phase 2 (Phase 2)Oct 24, 2023Agyany Pharma LTD
NCT05778617Phase 3Sep 30, 2023University of London
NCT05959850Phase 2Jun 13, 2023Calvary Health Care Bethlehem, Concord Repatriation General Hospital, Flinders University, The Florey Institute of Neuroscience and Mental Health, University of Queensland
NCT05830396Phase 2/Phase 3 (Phase 3)May 31, 2023University of Groningen
NCT05663905Phase 4Dec 31, 2022National University of Malaysia
NCT05558878N/AOct 1, 2022Ain Shams University
NCT05287503Phase 2Feb 15, 2022Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, IRCCS National Neurological Institute C. Mondino Foundation, University of Campania Luigi Vanvitelli
NCT04588285Phase 2Dec 1, 2020Helse Bergen, Helse Fonna, University of Oslo
NCT04405596Phase 1/Phase 2 (Phase 2)Sep 30, 2020University of Western Ontario
NCT03843541Phase 3Apr 17, 2019Zambon
NCT03950050Phase 2Mar 1, 2019Hebrew University
NCT03583658Phase 3Jun 30, 2018Sanofi
NCT03415269Phase 2Feb 28, 2018Sanofi, University of Hull
NCT02941822Phase 2Dec 1, 2016Cure Parkinson's Trust, PRO.MED.CS Praha a.s - Czech Republic, University of London
NCT02914366Phase 2Nov 1, 2015University of Western Ontario, Weston Foundation
NCT02792946Phase 3Nov 1, 2015Hyundai
NCT02373891Phase 1Apr 1, 2014Hyundai, Yonsei University
NCT02036775Phase 1Mar 1, 2014Boehringer Ingelheim
Showing 20 of 34 trials
Page 1 / 2

Organizations

Research & Development (33)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Boehringer IngelheimFor profit101031999
HyundaiFor profit4422012
Agyany Pharma LTDFor profit2222023
SanofiFor profit2122018
University of LondonAcademic/Hospital2222016
University of Western OntarioAcademic/Hospital2212015
Yonsei UniversityAcademic/Hospital2012013
Ain Shams UniversityAcademic/Hospital1112022
B.I. South Africa (Pty.) Ltd.For profit1012005
Calvary Health Care BethlehemAcademic/Hospital1012023
Concord Repatriation General HospitalAcademic/Hospital1012023
Cure Parkinson's TrustAcademic/Hospital1012016
Flinders UniversityAcademic/Hospital1012023
Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaAcademic/Hospital1112022
Hallym UniversityAcademic/Hospital1112011
Hanmi PharmaceuticalFor profit1112012
Hebrew UniversityAcademic/Hospital1112019
Helse BergenAcademic/Hospital1012020
Helse FonnaAcademic/Hospital1112020
IRCCS National Neurological Institute C. Mondino FoundationAcademic/Hospital1012022
33 organizations
Page 1 / 2